Carregant...
Lanreotide in the prevention and management of high-output ileostomy after colorectal cancer surgery
Objective: Patients with stage III and high-risk stage II colorectal cancer (CRC) are advised to initiate adjuvant treatment as soon as feasible and certainly before 8 to 12 weeks after resection of the tumor. A protective ileostomy is often constructed during surgery to protect a primary anastomosi...
Guardat en:
| Publicat a: | J Drug Assess |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5990955/ https://ncbi.nlm.nih.gov/pubmed/29888099 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21556660.2018.1467916 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|